Evidence map›Paper›PMID 33907370›Full record

ArticleMolecular vision2021

SAHA is neuroprotective in in vitro and in situ models of retinitis pigmentosa.

Nathan R Perron, Cécile Nasarre, Mausumi Bandyopadhyay, Craig C Beeson, Baerbel Rohrer

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nathan R PerronDepartment of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC.
Cécile NasarreDepartment of Ophthalmology, Medical University of South Carolina, Charleston, SC.
Mausumi BandyopadhyayDepartment of Ophthalmology, Medical University of South Carolina, Charleston, SC.
Craig C BeesonDepartment of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC.
Baerbel RohrerDepartment of Ophthalmology, Medical University of South Carolina, Charleston, SC.
Medical University of South Carolina · US

Funding

Alternative Pathway of Complement Activation in Age-Related Macular DegenerationR01EY019320 · NEI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ROHRER, BAERBEL · 2010 to 2014
$2.1M
NEI NIH HHS R01 EY019320
6 · The paper itself

Abstract

purposeRecent reports linking HDAC6 to mitochondrial turnover and neurodegeneration led us to hypothesize that an inhibitor such as Vorinostat (suberoylanilide hydroxamic acid, SAHA) may reduce mitochondrial damage found in retinitis pigmentosa (RP), a progressive neurodegenerative disease of the eye. Here we tested the efficacy of SAHA for its ability to protect photoreceptors in in-vitro and in-situ models of RP. As the stressor, we focused on calcium overload. Calcium is one of the main drivers of cell death, and is associated with rod loss in the rd1 mouse retina, which harbors a mutation in the Pde6b gene similar to that found in human patients suffering from autosomal recessive RP.

methodMurine photoreceptor cell line (661W) were exposed to agents that led to calcium stress. Cell survival and redox capacity were measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, real-time changes in cellular metabolism were assessed using the Seahorse Biosciences XF24 analyzer, and mitochondrial fission-fusion using imaging. In-situ, neuroprotection was assessed in RPE/retina organ cultures of the rd1 mouse. SAHA effects on cell survival were compared in 661W cells with those of the specific HDAC6 inhibitor tubastatin A, and those on protein acetylation by Western blotting.

resultsIn stressed 661W cells, SAHA was found to increase cell survival that was associated with improved mitochondrial respiration and reduced mitochondrial fission. The protective effects of SAHA were also observed on photoreceptor cell survival in whole retinal organ explants of the rd1 mouse. Even though tubastatin A was ineffective in increasing cell survival in 661W cells, HDAC6 activity was confirmed in 661W cells after SAHA treatment with protein acetylation specific for HDAC6, defined by an increase in tubulin, but not histone acetylation.

conclusionsSAHA was found to protect mitochondria from damage, and concomitantly reduced photoreceptor cell death in cell and organ cultures. The lack of activity of tubastatin A suggests that there must be an additional mechanism of action involved in the protective mechanism of SAHA that is responsible for its neuroprotection. Overall, SAHA may be a useful treatment for the prevention of photoreceptor degeneration associated with human RP. The results are discussed in the context of the effects of inhibitors that target different classes and members of the HDAC family and their effects on rod versus cone survival.

Indexed as

Disease Models, AnimalAnimalsBlotting, WesternCell LineCell SurvivalHistone Deacetylase InhibitorsMiceMitochondriaMitochondrial DiseasesNADH, NADPH OxidoreductasesNeuroprotective AgentsOrgan Culture TechniquesPhotoreceptor Cells, VertebrateRetinitis PigmentosaVorinostatHistone Deacetylase InhibitorsNADH, NADPH OxidoreductasesNeuroprotective AgentsVorinostat

Identifiers

PMID33907370
PMCPMC8056468
OpenAlexW3159723144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.